Top Stories
The Supreme Court denied an appeal from six drugmakers to halt Medicare drug pricing negotiations under the Inflation Reduction Act (IRA).
The Chinese firm's oral small-molecule GLP-1 agonist succeeded in a pivotal obesity study.
The TROP2-targeting antibody-drug conjugate sacituzumab tirumotecan significantly improved overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.
The pact aims to address challenging and historically "undruggable" targets, with a particular focus on antibody-Helicon conjugates.
The oral small molecule aldosterone synthase inhibitor was approved by the FDA for hypertension.
Conference News
LUND, SE / ACCESS Newswire / May 19, 2026 / Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026."The first quarter of 2026 reflects both stron...
LONDON and PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION, a tumor-activated ...
CBL-514, when combined separately with two leading GLP-1R-based weight-loss therapies, semaglutide and tirzepatide, demonstrated enhanced weight loss, attenuated post-discontinuation weight regain, an...
San Francisco, California, May 18, 2026 — New research published online today in the American Journal of Psychiatry finds that low-dose buprenorphine, given after a single ketamine infusion, significa...
New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages Primary results from the persevERA study on t...
